Zobrazeno 1 - 10
of 44
pro vyhledávání: '"V. K. Fedyaeva"'
Autor:
M. V. Shestakova, A. Yu. Mayorov, E. V. Surkova, G. R. Galstyan, A. S. Ametov, M. B. Antsiferov, E. G. Starostina, O. G. Melnikova, L. I. Ibragimova, E. A. Andrianova, E. V. Ershova, I. A. Karpova, I. V. Kononenko, A. V. Tiselko, V. K. Fedyaeva
Publikováno v:
Сахарный диабет, Vol 25, Iss 3, Pp 299-304 (2022)
According to the decision of the WHO, therapeutic education (TE) of patients is an independent branch of medicine and an essential component of the treatment of chronic diseases, primarily diabetes mellitus and obesity. TE is implemented through the
Externí odkaz:
https://doaj.org/article/830287ca80f84a2cbd1f061cfd3019ef
Autor:
N. Z. Musina, V. V. Omelyanovskiy, R. V. Gostischev, O. A. Sukhorukikh, V. K. Fedyaeva, N. N. Sisigina, D. G. Shchurov
Publikováno v:
Фармакоэкономика, Vol 13, Iss 4, Pp 438-451 (2021)
This article contains the aims and main principles of the concept of value-based healthcare (VBHC). The relevance of the implementation of this approach into the Russian healthcare system results from the fact that during the control and payment for
Externí odkaz:
https://doaj.org/article/ac432edf7d1146239fa449db35811c2b
Publikováno v:
Фармакоэкономика, Vol 12, Iss 4, Pp 327-332 (2020)
Introduction. The RAND/UCLA system is commonly used in healthcare economics as it allows one to consider both the relevant scientific data and the opinion of leading experts for deciding on the specifics of medical care.Objective. To analyze the reco
Externí odkaz:
https://doaj.org/article/3e1e89bbd1ce4eec869c4a74c2c09521
Publikováno v:
Фармакоэкономика, Vol 12, Iss 4, Pp 318-326 (2020)
Methods of payment to care providers constitute an essential part of the healthcare financing system; these mechanisms determine the motivation of service providers. Throughout the history of public health care, the payment methods have been graduall
Externí odkaz:
https://doaj.org/article/c70d0a253dc245cba61fa6fb618a2b0d
Autor:
V. K. Fedyaeva, U. N. Dmitrieva, N. I. Juravleva, N. I. Juravlev, M. Yu. Kovaleva, A. S. Korobkina, O. A. Sukhorukikh, A. A. Pashkina
Publikováno v:
Фармакоэкономика, Vol 12, Iss 3, Pp 239-245 (2019)
Introduction. In 2016-2018, the approaches to the development and use of clinical guidelines in the Russian Federation underwent substantial changes. As part of this work, legal aspects of clinical guidelines were modified. The present review, conduc
Externí odkaz:
https://doaj.org/article/b0bac563adb34db29912a9bae9dd588c
Autor:
T. P. Bezdenezhnykh, N. Z. Musina, V. K. Fedyaeva, T. S. Tepcova, V. A. Lemeshko, V. V. Omelyanovsky
Publikováno v:
Фармакоэкономика, Vol 11, Iss 4, Pp 73-80 (2019)
The article reviews international methodological guidelines, regulatory documents and existing approaches to the determination of the costeffectiveness threshold (CeT), also known as the willingness-to-pay threshold (WTP), the threshold value of the
Externí odkaz:
https://doaj.org/article/411f82ed62f849f89ce7b76edc6cc21c
Autor:
T. S. Teptsova, T. P. Bezdenezhnyh, V. K. Fedyaeva, N. Z Musina, G. R. Hachatryan, V. V. Tarasov
Publikováno v:
Фармакоэкономика, Vol 11, Iss 3, Pp 13-22 (2018)
The aim was to develop a methodology for determining the willingness to pay threshold (WTPT) and its upper limit value within the Russian health care system.Materials and methods. WTPT was calculated based on the shadow budget price (i. e. determinin
Externí odkaz:
https://doaj.org/article/328fb7373f08455ea7b23e2dcf1ba3c1
Publikováno v:
Фармакоэкономика, Vol 11, Iss 3, Pp 3-7 (2018)
In the article, we analyze the current version of Government Regulation No. 871 where the principles of health technologies assessment (HTA) and the reimbursement strategies in Russia have been put forward. We conclude that the HTA methodology in Rus
Externí odkaz:
https://doaj.org/article/3891d6d1e3c1499095d1f9828ec75133
Publikováno v:
Фармакоэкономика, Vol 10, Iss 4, Pp 25-30 (2018)
The current approaches to the drug pricing commonly used worldwide allow for incorporating the therapeutic value of the drug into its consumer price. The drug pricing system existing in the Russian Federation restricts the availability of highly effe
Externí odkaz:
https://doaj.org/article/cbc694845ede468bb4492485ad43040d
Autor:
N. Z. Musina, V. K. Fedyaeva, V. V. Omel’yanovskii, G. R. Khachatryan, K. V. Gerasimova, V. A. Lemeshko, K. P. Konchits
Publikováno v:
Фармакоэкономика, Vol 10, Iss 3, Pp 66-74 (2017)
A set of criteria for assessing the innovative potential of drugs (therapeutic value) have been developed and are widely used elsewhere. These approaches allow the state (the payer) to assess the clinical significance of a new medical product and mak
Externí odkaz:
https://doaj.org/article/5229337fec764b4ea60ec04d13d28c0c